Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksABC.L Regulatory News (ABC)

  • There is currently no data for ABC

Director/PDMR Shareholding

3 Dec 2008 11:59

RNS Number : 4632J
ABCAM Plc
03 December 2008
 



For immediate release

3 December 2008

ABCAM PLC

("Abcam" or "the Company")

ABCAM PLC SHARE INCENTIVE PLAN 

Directors' Dealings

On 7 November 2008 Abcam announced that as a result of transactions on 6 November 2008 by the Abcam plc Share Incentive Plan -"the Plan" - (an HMRC approved all employee share purchase plan adopted by the Company's shareholders at the Company's AGM on 3 November 2008), Jonathan Milner, Jeff Iliffe and Jim Warwick, Executive Directors of the Company, had each been awarded 649 "Free shares". The beneficial ownership of these shares will pass to the Executive Directors on 6 November 2011 subject to their continued employment with Abcam plc.

The final dividend of 4.56 pence per share which was approved at the AGM was paid on 28 November 2008. Pursuant to the terms of the Plan, on 2 December 2008, the dividend paid on the "Free shares" granted to the Executive Directors as detailed above was used to purchase additional shares at 475p each to be held on behalf of the Executive Directors in the Abcam plc Share Incentive Plan. These shares are as detailed below: 

Dividend shares  purchased

No of shares held in the

Plan on 2 December 2008

Including the dividend

shares

Jeff Iliffe

6

1,273

Jonathan Milner

6

1,273

Jim Warwick

6

1,273

For further information please contact:

Abcam
+ 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
 
Jeff Iliffe, Chief Financial Officer
www.abcam.com
 
 
 
Numis Securities
+ 44 (0) 20 7776 1500
Nominated Adviser - Michael Meade, Nick Westlake
Corporate Broking - James Black
 
 
 
Buchanan Communications
+ 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson
 
 
 

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 47,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs over 200 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSFXLFBVLBEFBZ
Date   Source Headline
2nd Mar 201812:43 pmRNSTotal Voting Rights
19th Feb 20188:44 amRNSBlock listing Interim Review
2nd Feb 20185:57 pmRNSHolding(s) in Company
1st Feb 201812:26 pmRNSTotal Voting Rights
22nd Jan 20187:00 amRNSAbcam Signs Exclusive License Agreement with Roche
18th Jan 201812:02 pmRNSHolding(s) in Company
8th Jan 201812:00 pmRNSAbcam present at J.P. Morgan Healthcare Conference
5th Jan 20187:00 amRNSHalf Year Trading Update
3rd Jan 20189:10 amRNSTotal Voting Rights
12th Dec 201710:37 amRNSDirector/PDMR Shareholding
1st Dec 20173:07 pmRNSTotal Voting Rights
15th Nov 20177:00 amRNSResult of AGM and Directorate Change
14th Nov 20177:00 amRNSAGM Statement
6th Nov 20174:48 pmRNSDirector/PDMR Shareholding
6th Nov 20174:42 pmRNSDirector/PDMR Shareholding
6th Nov 20174:40 pmRNSDirector/PDMR Shareholding
1st Nov 20174:46 pmRNSTotal Voting Rights
30th Oct 20179:55 amRNSDirector/PDMR Shareholding
17th Oct 20173:06 pmRNSHolding(s) in Company
11th Oct 20177:00 amRNSDirectorate Change
3rd Oct 201711:16 amRNSTotal Voting Rights
22nd Sep 20173:32 pmRNSAnnual Financial Report
22nd Sep 20177:00 amRNSDirector/PDMR Shareholding
18th Sep 20174:36 pmRNSDirector/PDMR Shareholding
11th Sep 20177:00 amRNSPreliminary Results
1st Sep 20179:41 amRNSTotal Voting Rights
25th Aug 201711:00 amRNSHolding(s) in Company
17th Aug 201710:00 amRNSHolding(s) in Company
9th Aug 20173:18 pmRNSBlock listing Interim Review
1st Aug 20179:45 amRNSTotal Voting Rights
27th Jul 20177:00 amRNSPre-Close Period Update
3rd Jul 20179:54 amRNSTotal Voting Rights
7th Jun 20174:23 pmRNSDirector/PDMR Shareholding
1st Jun 20172:41 pmRNSTotal Voting Rights
18th May 20173:17 pmRNSApplication for admission to trading
18th May 20177:00 amRNSFinal Performance-Based AxioMx Milestone Payment
3rd May 201711:25 amRNSDirector/PDMR Shareholding
2nd May 201710:27 amRNSTotal Voting Rights
18th Apr 20172:24 pmRNSDirector/PDMR Shareholding
10th Apr 20173:37 pmRNSDirector/PDMR Shareholding
3rd Apr 20171:53 pmRNSTotal Voting Rights
23rd Mar 20177:00 amRNSDirector/PDMR Shareholding
21st Mar 20177:00 amRNSDirector/PDMR Shareholding
6th Mar 20177:00 amRNSInterim Results
1st Mar 20174:05 pmRNSTotal Voting Rights
9th Feb 20178:52 amRNSBlock listing Interim Review
1st Feb 201712:09 pmRNSTotal Voting Rights
10th Jan 20177:00 amRNSHalf Year Trading Update
3rd Jan 20174:34 pmRNSTotal Voting Rights
15th Dec 201611:19 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.